|Last Price$59.70||Day Change (%)1.24%|
|Open Price$59.09||Day Change ($)0.73|
|Day Range58.87–59.78||52-Week Range52.49–63.62|
As of Wed 5/27/2015 1:01:00 PM | USD
Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
Merck Profit Pressured by Financing for Sigma-Aldrich Deal
Research and Markets: European Liquid Chromatography Reagents Market Report 2015 - Column & Planar Chromatography Reagents
New Push Ties Cost of Drugs to How Well They Work
Research and Markets: Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020
Research and Markets: Global Breast Cancer Monoclonal Antibodies Market Outlook 2020
Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
Merck shares up 4.5% as company beats profit, sales estimates and raises outlook
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
New products will secure the drug firm’s wide moat and help increase the firm’s valuation over time, writes Morningstar’s Damien Conover.